The Treatment of the Behavioral Sequelae of Autism with Dextromethorphan: A Case Report
- 155 Downloads
Dextromethorphan is the d-isomer of levorphenol, and an ingredient in antitussive preparations. A 10 year-old male diagnosed with Autistic Disorder, Pervasive Developmental Disorder, and Generalized Anxiety Disorder was administered this medication initially to treat a medical condition. This became a quasi-experimental ABAB design (A = baseline, B = treatment), with improvements during treatment phases shown in tracked behavioral data and anecdotal reports. Several candidate mechanisms to explain the improvements are offered, including glutamate receptor antagonism. While dextromethorphan is not commonly administered for the treatment of behavioral challenges in this or any population, the results suggest the need for larger-scale, adequately controlled, and methodologically rigorous studies of the potential clinical effects of dextromethorphan.
KeywordsAutism dextromethorphan glutamate
Unable to display preview. Download preview PDF.
- McDougle, C. J. (2002). Current and Emerging Therapeutics of Autistic Disorder and Related Pervasive Developmental Disorders.In K. L. Davis, D. Charney, J. T. Coyle, & C Nemeroff(Eds.), .(pp. 566–577). Philadelphia: Lippincott Williams andWilkins.Google Scholar
- Phillips, J. A., Hamid, R., & McGrew, S. (1999, October). Effects of dextromethorphan in autistic children with abnormal amino acid profiles. Program 2861 presented at the annual meeting of the American Society of Human Genetics (ASHG), San Francisco, CAGoogle Scholar